{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:18:55Z","timestamp":1781335135980,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,10,9]],"date-time":"2006-10-09T00:00:00Z","timestamp":1160352000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1186\/1471-2261-6-40","type":"journal-article","created":{"date-parts":[[2006,10,10]],"date-time":"2006-10-10T06:27:37Z","timestamp":1160461657000},"source":"Crossref","is-referenced-by-count":21,"title":["Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1"],"prefix":"10.1186","volume":"6","author":[{"given":"Anders EA","family":"Dahm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baard","family":"Birkenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Hansen","family":"Ree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Morten","family":"Sandset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,10,9]]},"reference":[{"key":"131_CR1","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0140-6736(96)07113-9","volume":"348","author":"E Daly","year":"1996","unstructured":"Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996, 348: 977-980. 10.1016\/S0140-6736(96)07113-9.","journal-title":"Lancet"},{"key":"131_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(96)07308-4","volume":"348","author":"F Grodstein","year":"1996","unstructured":"Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH: Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996, 348: 983-987. 10.1016\/S0140-6736(96)07308-4.","journal-title":"Lancet"},{"key":"131_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0140-6736(96)07114-0","volume":"348","author":"H Jick","year":"1996","unstructured":"Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996, 348: 981-983. 10.1016\/S0140-6736(96)07114-0.","journal-title":"Lancet"},{"key":"131_CR4","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1055\/s-0037-1614156","volume":"84","author":"E Hoibraaten","year":"2000","unstructured":"Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM: Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost. 2000, 84: 961-967.","journal-title":"Thromb Haemost"},{"key":"131_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1365-2796.1995.tb00896.x","volume":"238","author":"T Koster","year":"1995","unstructured":"Koster T, Small RA, Rosendaal FR, Helmerhorst FM: Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Intern Med. 1995, 238: 31-37.","journal-title":"J Intern Med"},{"key":"131_CR6","doi-asserted-by":"crossref","unstructured":"Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995, 346: 1575-1582.","DOI":"10.1016\/S0140-6736(95)91926-0"},{"key":"131_CR7","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"SR Cummings","year":"1999","unstructured":"Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999, 281: 2189-2197. 10.1001\/jama.281.23.2189.","journal-title":"JAMA"},{"key":"131_CR8","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093\/jnci\/90.18.1371.","journal-title":"J Natl Cancer Inst"},{"key":"131_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001\/jama.288.3.321.","journal-title":"JAMA"},{"key":"131_CR10","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1161\/01.STR.0000015345.61324.3F","volume":"33","author":"JM Kemmeren","year":"2002","unstructured":"Kemmeren JM, Tanis BC, van den Bosch MA, Bollen EL, Helmerhorst FM, van der Graaf Y, Rosendaal FR, Algra A: Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke. 2002, 33: 1202-1208. 10.1161\/01.STR.0000015345.61324.3F.","journal-title":"Stroke"},{"key":"131_CR11","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa003216","volume":"345","author":"BC Tanis","year":"2001","unstructured":"Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, van der Graaf Y, Rosendaal FR: Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 2001, 345: 1787-1793. 10.1056\/NEJMoa003216.","journal-title":"N Engl J Med"},{"key":"131_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1046\/j.1365-2141.2001.03111.x","volume":"115","author":"E Hoibraaten","year":"2001","unstructured":"Hoibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM: Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol. 2001, 115: 415-420. 10.1046\/j.1365-2141.2001.03111.x.","journal-title":"Br J Haematol"},{"key":"131_CR13","doi-asserted-by":"publisher","first-page":"S375","DOI":"10.1016\/S0002-9378(99)70699-X","volume":"180","author":"J Rosing","year":"1999","unstructured":"Rosing J, Tans G: Effects of oral contraceptives on hemostasis and thrombosis. Am J Obstet Gynecol. 1999, 180: S375-S382. 10.1016\/S0002-9378(99)70699-X.","journal-title":"Am J Obstet Gynecol"},{"key":"131_CR14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1055\/s-0038-1656192","volume":"2","author":"T Astrup","year":"1958","unstructured":"Astrup T: The haemostatic balance. Thromb Diath Haemorrh. 1958, 2: 347-357.","journal-title":"Thromb Diath Haemorrh"},{"key":"131_CR15","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1046\/j.1538-7836.2003.00264.x","volume":"1","author":"FR Rosendaal","year":"2003","unstructured":"Rosendaal FR, van Hylckama Vlieg A, Tanis BC, Helmerhorst FM: Estrogens, progestogens and thrombosis. J Thromb Haemost. 2003, 1: 1371-1380. 10.1046\/j.1538-7836.2003.00264.x.","journal-title":"J Thromb Haemost"},{"key":"131_CR16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ejca.2004.07.035","volume":"41","author":"JF Robertson","year":"2005","unstructured":"Robertson JF, Come SE, Jones SE, Beex L, Kaufmann M, Makris A, Nortier JW, Possinger K, Rutqvist LE: Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer. 2005, 41: 346-356. 10.1016\/j.ejca.2004.07.035.","journal-title":"Eur J Cancer"},{"key":"131_CR17","doi-asserted-by":"publisher","first-page":"8869","DOI":"10.1073\/pnas.87.22.8869","volume":"87","author":"MS Bajaj","year":"1990","unstructured":"Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP: Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci U S A. 1990, 87: 8869-8873. 10.1073\/pnas.87.22.8869.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"131_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev.med.46.1.103","volume":"46","author":"GJJ Broze","year":"1995","unstructured":"Broze GJJ: Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med. 1995, 46: 103-112. 10.1146\/annurev.med.46.1.103.","journal-title":"Annu Rev Med"},{"key":"131_CR19","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1182\/blood-2002-10-3188","volume":"101","author":"A Dahm","year":"2003","unstructured":"Dahm A, van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM: Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood. 2003, 101: 4387-4392. 10.1182\/blood-2002-10-3188.","journal-title":"Blood"},{"key":"131_CR20","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1161\/01.CIR.0000120705.55512.EC","volume":"109","author":"PE Morange","year":"2004","unstructured":"Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I: Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation. 2004, 109: 1343-1348. 10.1161\/01.CIR.0000120705.55512.EC.","journal-title":"Circulation"},{"key":"131_CR21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2174\/1389450054863699","volume":"6","author":"H Negaard","year":"2005","unstructured":"Negaard H, Dahm A, Sandset PM, Iversen PO, Ostenstad B: Angiogenesis and hemostasis in hematological neoplasias. Curr Drug Targets. 2005, 6: 683-699. 10.2174\/1389450054863699.","journal-title":"Curr Drug Targets"},{"key":"131_CR22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1160\/TH04-06-0387","volume":"92","author":"SA Mousa","year":"2004","unstructured":"Mousa SA, Mohamed S: Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost. 2004, 92: 627-633.","journal-title":"Thromb Haemost"},{"key":"131_CR23","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/annonc\/mdh437","volume":"15","author":"M Erman","year":"2004","unstructured":"Erman M, Abali H, Oran B, Haznedaroglu IC, Canpinar H, Kirazli S, Celik I: Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?. Ann Oncol. 2004, 15: 1622-1626. 10.1093\/annonc\/mdh437.","journal-title":"Ann Oncol"},{"key":"131_CR24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1055\/s-0037-1615717","volume":"85","author":"E Hoibraaten","year":"2001","unstructured":"Hoibraaten E, Qvigstad E, Andersen TO, Mowinckel MC, Sandset PM: The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial. Thromb Haemost. 2001, 85: 775-781.","journal-title":"Thromb Haemost"},{"key":"131_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/(SICI)1096-8652(199903)60:3<175::AID-AJH1>3.0.CO;2-X","volume":"60","author":"GM Harris","year":"1999","unstructured":"Harris GM, Stendt CL, Vollenhoven BJ, Gan TE, Tipping PG: Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am J Hematol. 1999, 60: 175-180. 10.1002\/(SICI)1096-8652(199903)60:3<175::AID-AJH1>3.0.CO;2-X.","journal-title":"Am J Hematol"},{"key":"131_CR26","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1172\/JCI107470","volume":"52","author":"EA Jaffe","year":"1973","unstructured":"Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973, 52: 2745-2756.","journal-title":"J Clin Invest"},{"key":"131_CR27","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1093\/nar\/30.9.e36","volume":"30","author":"MW Pfaffl","year":"2002","unstructured":"Pfaffl MW, Horgan GW, Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002, 30: e36-10.1093\/nar\/30.9.e36.","journal-title":"Nucleic Acids Res"},{"key":"131_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0049-3848(00)00228-0","volume":"99","author":"AS Bilsel","year":"2000","unstructured":"Bilsel AS, Onaran N, Moini H, Emerk K: Long-term effect of 17beta-estradiol and thrombin on tissue factor pathway inhibitor release from HUVEC. Thromb Res. 2000, 99: 173-178. 10.1016\/S0049-3848(00)00228-0.","journal-title":"Thromb Res"},{"key":"131_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jsbmb.2004.12.026","volume":"94","author":"RA Shirk","year":"2005","unstructured":"Shirk RA, Zhang Z, Winneker RC: Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat. J Steroid Biochem Mol Biol. 2005, 94: 361-368. 10.1016\/j.jsbmb.2004.12.026.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"131_CR30","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1161\/hc1102.105267","volume":"105","author":"T Simoncini","year":"2002","unstructured":"Simoncini T, Genazzani AR, Liao JK: Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation. 2002, 105: 1368-1373. 10.1161\/hc1102.105267.","journal-title":"Circulation"},{"key":"131_CR31","doi-asserted-by":"publisher","first-page":"7460","DOI":"10.1074\/jbc.M411565200","volume":"280","author":"CM Klinge","year":"2005","unstructured":"Klinge CM, Blankenship KA, Risinger KE, Bhatnagar S, Noisin EL, Sumanasekera WK, Zhao L, Brey DM, Keynton RS: Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J Biol Chem. 2005, 280: 7460-7468. 10.1074\/jbc.M411565200.","journal-title":"J Biol Chem"},{"key":"131_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.mce.2004.08.004","volume":"227","author":"H Savolainen-Peltonen","year":"2004","unstructured":"Savolainen-Peltonen H, Luoto NM, Kangas L, Hayry P: Selective estrogen receptor modulators prevent neointima formation after vascular injury. Mol Cell Endocrinol. 2004, 227: 9-20. 10.1016\/j.mce.2004.08.004.","journal-title":"Mol Cell Endocrinol"},{"key":"131_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0049-3848(99)00040-7","volume":"95","author":"L Petit","year":"1999","unstructured":"Petit L, Lesnik P, Dachet C, Hugou I, Moreau M, Chapman J, Rouis M: The promoter of human tissue factor pathway inhibitor gene: identification of potential regulatory elements. Thromb Res. 1999, 95: 255-262. 10.1016\/S0049-3848(99)00040-7.","journal-title":"Thromb Res"},{"key":"131_CR34","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1093\/emboj\/19.17.4688","volume":"19","author":"G Flouriot","year":"2000","unstructured":"Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G, Sonntag-Buck V, Gannon F: Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO J. 2000, 19: 4688-4700. 10.1093\/emboj\/19.17.4688.","journal-title":"EMBO J"},{"key":"131_CR35","doi-asserted-by":"publisher","first-page":"5930","DOI":"10.1073\/pnas.97.11.5930","volume":"97","author":"KS Russell","year":"2000","unstructured":"Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR: Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci U S A. 2000, 97: 5930-5935. 10.1073\/pnas.97.11.5930.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"131_CR36","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1161\/01.CIR.0000043805.11780.F5","volume":"107","author":"GA Figtree","year":"2003","unstructured":"Figtree GA, McDonald D, Watkins H, Channon KM: Truncated estrogen receptor alpha 46-kDa isoform in human endothelial cells: relationship to acute activation of nitric oxide synthase. Circulation. 2003, 107: 120-126. 10.1161\/01.CIR.0000043805.11780.F5.","journal-title":"Circulation"},{"key":"131_CR37","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1126\/science.1106943","volume":"307","author":"CM Revankar","year":"2005","unstructured":"Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER: A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005, 307: 1625-1630. 10.1126\/science.1106943.","journal-title":"Science"},{"key":"131_CR38","doi-asserted-by":"publisher","first-page":"35684","DOI":"10.1074\/jbc.M101097200","volume":"276","author":"AL Wijayaratne","year":"2001","unstructured":"Wijayaratne AL, McDonnell DP: The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem. 2001, 276: 35684-35692. 10.1074\/jbc.M101097200.","journal-title":"J Biol Chem"},{"key":"131_CR39","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1210\/me.7.7.879","volume":"7","author":"KJ Kaneko","year":"1993","unstructured":"Kaneko KJ, Furlow JD, Gorski J: Involvement of the coding sequence for the estrogen receptor gene in autologous ligand-dependent down-regulation. Mol Endocrinol. 1993, 7: 879-888. 10.1210\/me.7.7.879.","journal-title":"Mol Endocrinol"},{"key":"131_CR40","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1210\/endo-124-5-2577","volume":"124","author":"AH Ree","year":"1989","unstructured":"Ree AH, Landmark BF, Eskild W, Levy FO, Lahooti H, Jahnsen T, Aakvaag A, Hansson V: Autologous down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors in MCF-7 cells: an inverse correlation to progesterone receptor levels. Endocrinology. 1989, 124: 2577-2583.","journal-title":"Endocrinology"},{"key":"131_CR41","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.1128\/MCB.25.13.5417-5428.2005","volume":"25","author":"CC Valley","year":"2005","unstructured":"Valley CC, Metivier R, Solodin NM, Fowler AM, Mashek MT, Hill L, Alarid ET: Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus. Mol Cell Biol. 2005, 25: 5417-5428. 10.1128\/MCB.25.13.5417-5428.2005.","journal-title":"Mol Cell Biol"},{"key":"131_CR42","doi-asserted-by":"crossref","first-page":"871s","DOI":"10.1158\/1078-0432.871s.11.2","volume":"11","author":"DP McDonnell","year":"2005","unstructured":"McDonnell DP: The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. Clin Cancer Res. 2005, 11: 871s-877s.","journal-title":"Clin Cancer Res"},{"key":"131_CR43","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1210\/en.141.10.3908","volume":"141","author":"MA Richardson","year":"2000","unstructured":"Richardson MA, Berg DT, Calnek DS, Ciaccia AV, Joyce DE, Grinnell BW: 17beta-estradiol, but not raloxifene, decreases thrombomodulin in the antithrombotic protein C pathway. Endocrinology. 2000, 141: 3908-3911. 10.1210\/en.141.10.3908.","journal-title":"Endocrinology"},{"key":"131_CR44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/01.RES.0000136521.70093.f1","volume":"95","author":"LH Smith","year":"2004","unstructured":"Smith LH, Coats SR, Qin H, Petrie MS, Covington JW, Su M, Eren M, Vaughan DE: Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor alpha and estrogen receptor beta in endothelial cells. Circ Res. 2004, 95: 269-275. 10.1161\/01.RES.0000136521.70093.f1.","journal-title":"Circ Res"},{"key":"131_CR45","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1161\/01.RES.0000139435.06532.cf","volume":"95","author":"N Madamanchi","year":"2004","unstructured":"Madamanchi N, Niu XL, Runge MS: A new slice of pie? Estrogen regulation of plasminogen activator inhibitor-1. Circ Res. 2004, 95: 228-229. 10.1161\/01.RES.0000139435.06532.cf.","journal-title":"Circ Res"},{"key":"131_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2004.09.014","volume":"116","author":"F Cosman","year":"2005","unstructured":"Cosman F, Baz-Hecht M, Cushman M, Vardy MD, Cruz JD, Nieves JW, Zion M, Lindsay R: Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb Res. 2005, 116: 1-13. 10.1016\/j.thromres.2004.09.014.","journal-title":"Thromb Res"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2261-6-40\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2261-6-40.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2261-6-40","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2261-6-40.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T07:48:59Z","timestamp":1683618539000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/1471-2261-6-40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,9]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["131"],"URL":"https:\/\/doi.org\/10.1186\/1471-2261-6-40","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,9]]},"article-number":"40"}}